4.7 Review

Methylation biomarkers for early cancer detection and diagnosis: Current and future perspectives

期刊

EUROPEAN JOURNAL OF CANCER
卷 178, 期 -, 页码 91-113

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.ejca.2022.10.015

关键词

Methylation; Biomarkers; Early detection; Diagnosis; Cancer

类别

向作者/读者索取更多资源

The recent increase in cancer biomarker research has led to new insights in the field. Technological breakthroughs, such as long read sequencing and microarrays, have enabled high throughput profiling of biomarkers, while advances in bioinformatic tools have made reliable and accurate biomarkers a reality. These changes have renewed interest in biomarker research and provided opportunities for enhancing cancer management and early disease detection.
The increase in recent scientific studies on cancer biomarkers has brought great new insights into the field. Moreover, novel technological breakthroughs such as long read sequencing and microarrays have enabled high throughput profiling of many biomarkers, while advances in bioinformatic tools have made the possibility of developing highly reliable and accurate biomarkers a reality. These changes triggered renewed interest in biomarker research and provided tremendous opportunities for enhancing cancer management and improving early disease detection. DNA methylation alterations are known to accompany and contribute to carcinogenesis, making them promising biomarkers for cancer, namely due to their stability, frequency and accessibility in bodily fluids. The advent of newer minimally invasive experimental methods such as liquid biopsies provide the perfect setting for methylation-based biomarker development and application. Despite their huge potential, accurate and robust biomarkers for the conclusive diagnosis of most cancer types are still not routinely used, hence a strong need for sustained research in this field is still needed. This review provides a brief exposition of current methylation biomarkers for cancer diagnosis and early detection, including markers already in clinical use as well as various upcoming ones. It also outlines how recent big data and novel technologies will revolutionise the next generation of cancer tests in supplementing or replacing currently existing invasive techniques. (c) 2022 Elsevier Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据